Avacincaptad Pegol clinical trials
Avacincaptad Pegol is named as an intervention in 3 current clinical trials in our USA, UK, Germany, Spain, Poland, Switzerland, Austria, Czechia, Portugal, Canada and Japan registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is ONL Therapeutics (1). The most-studied condition is Geographic Atrophy.
Where Avacincaptad Pegol is approved
All regulators →Of the three regulators tracked here, the first to approve Avacincaptad Pegol was the US, on 4 Aug 2023.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Avacincaptad Pegol patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Avacincaptad Pegol, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 6 listed patents; the last listed expires 11 Jul 2034 (US 11491176).
- Latest patent on the drug substance itself: 14 Feb 2027 (US 9617546).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Avacincaptad Pegol
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Avacincaptad Pegol works
All drug targets →- Complement C5 inhibitor InhibitorTarget: C5 complement C5ChEMBL only
- Macular degenerationPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297889, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12857, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Avacincaptad Pegol
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Avacincaptad Pegol
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445 · Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
|
Phase 2 | Recruiting | ONL Therapeutics | UK, USA, Germany, Spain, Poland, Switzerland, Austria, Czechia, Portugal, Canada |
|
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
NCT06970665 · ClinicalTrials.gov ↗ · Geographic Atrophy, Age-Related Macular Degeneration
|
Phase 4 | Active, closed | Astellas Pharma Inc | Japan |
|
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773 · Geographic Atrophy, Macular Degeneration
|
Observational | Active, closed | Astellas Pharma Global Development, Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Avacincaptad Pegol
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| ONL Therapeutics | 1 |
| Astellas Pharma Global Development, Inc | 1 |
| Astellas Pharma Inc | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Avacincaptad Pegol trials
How many clinical trials are testing Avacincaptad Pegol?
3 current trials in our USA, UK, Germany, Spain, Poland, Switzerland, Austria, Czechia, Portugal, Canada and Japan registers name Avacincaptad Pegol (also registered as ASP3021) as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are Avacincaptad Pegol trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in USA, 1 with sites in UK, 1 with sites in Germany, 1 with sites in Spain, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Portugal and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Avacincaptad Pegol clinical trials?
ONL Therapeutics (1), Astellas Pharma Global Development, Inc (1) and Astellas Pharma Inc (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Avacincaptad Pegol works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Avacincaptad Pegol works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Avacincaptad Pegol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.